Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle>

• Main Authors: Kristina A. Bryant (Author), Jodie McVernon (Author), Colin D. Marchant (Author), Terry Nolan (Author), Gary S. Marshall (Author), Peter Richmond (Author), Helen Marshall (Author), Michael Nissen (Author), Stephen B. Lambert (Author), Emmanuel Aris (Author), Narcisa Mesaros (Author), Jacqueline M. Miller (Author)
• Format: Book
• Published: Taylor & Francis Group, 2012-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.

Item Description

10.4161/hv.20357
2164-554X
2164-5515